NCT06332612View on ClinicalTrials.gov

Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 12, 2024

Primary Completion Date

December 30, 2024

Study Completion Date

January 6, 2025

Conditions
Oral Submucous Fibrosis
Interventions
DRUG

Metformin Hydrochloride

Group B will receive Metformin 500 mg thrice daily. Group C will receive topical cream metformin thrice daily.

DRUG

betamethasone dipropionate

Group 1will recieve topical cream betamethasone thrice daily

DRUG

Pentoxifylline

Group 1 will receive Pentoxifylline tablet 400 mg twice daily

Trial Locations (1)

74700

Ziauddin University, Karachi

All Listed Sponsors
lead

Ziauddin University

OTHER

NCT06332612 - Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial | Biotech Hunter | Biotech Hunter